Mitomycin C inhibits recurrent Avellino dystrophy after phototherapeutic keratectomy

Cornea. 2006 Feb;25(2):220-3. doi: 10.1097/01.ico.0000164830.79970.71.

Abstract

Purpose: To report 4 patients with Avellino corneal dystrophy (ACD) who were treated with 0.02% mitomycin C (MMC) during phototherapeutic keratectomy (PTK).

Methods: ACD was confirmed by polymorphism of the exon region in the BIGH3 gene using polymerase chain reaction followed by DNA sequencing analysis. Three patients with recurrent ACD and 1 patient with primary ACD underwent PTK. Intraoperative 0.02% MMC was applied topically with a soaked microsponge.

Results: There was no recurrence of ACD in the heterozygotes, but there were recurrences with best-corrected visual acuity of 20/30 in the 2 homozygotes.

Conclusion: Intraoperative use of topical 0.02% MMC in conjunction with PTK may prevent or delay the recurrence of ACD for at least for 1 year.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Corneal Dystrophies, Hereditary / drug therapy
  • Corneal Dystrophies, Hereditary / pathology
  • Corneal Dystrophies, Hereditary / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Intraoperative Period
  • Lasers, Excimer
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage*
  • Mitomycin / therapeutic use
  • Nucleic Acid Synthesis Inhibitors / administration & dosage*
  • Nucleic Acid Synthesis Inhibitors / therapeutic use
  • Ophthalmic Solutions
  • Photorefractive Keratectomy*
  • Secondary Prevention
  • Visual Acuity

Substances

  • Nucleic Acid Synthesis Inhibitors
  • Ophthalmic Solutions
  • Mitomycin